EGb 761 in the Syndrome of MCI With Concomitant CVD

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI + CVD.
Epistemonikos ID: 39e2cba48b800c780b704d7fb0091c526390742d
First added on: May 07, 2024